SARS-CoV-2 epitope-specific CD4+ memory T cell responses across COVID-19 disease severity and antibody durability
暂无分享,去创建一个
Michael D Healy | Kelsey K. Finn | Han Liu | M. Carrington | K. Flaherty | Xu G. Yu | D. Wesemann | G. Alter | M. Lichterfeld | Fatema Z. Chowdhury | D. Lingwood | S. Pillai | C. O’Callaghan | David Golan | A. Balazs | A. Luster | Kelly Judge | J. Moon | Julia Bals | Grace Holland | A. Griffin | Y. Yuki | Maureen P. Martin | D. Drew | Ryan W. Nelson | J. Fallon | A. Michell | M. Dougan | Nishant K. Singh | Yuting Lu | Yuezhou Chen | Y. Bartsch | M. Ghebremichael | J. Boucau | Pilar García-Broncano | Daniel S. Shin | M. Barbash | Xiaodong Lian | Bruce Walker | M. Carrington | K. Sheppard | J. Flannery | Daniel P. Worrall | N. Jilg | A. Sharpe | Xiaoming Sun | A. Zhu | Andrew Chan | E. Gettings | Kevin B. Einkauf | Joshua M. Chevalier | K. Armstrong | C. Hartana | Colline Wong | A. Rosenthal | K. Lefteri | Matt Osborn | Chenyan Jiang | P. Kaplonek | Marshall Karpell | Jinqing Liu | Yelizaveta Rassadkina | Kyra W. Seiger | Libera Sessa | S. Shin | Weiwei Sun | Hannah Ticheli | P. Allen | E. Lam | C. Sharr | J. Braley | Peggy S. Lai | Jonathan Z Li | Z. Manickas-Hill | R. McNamara | S. Nelson | Olivia L. Venezia | R. Majerus | Betelihem A Abayneh | Diane Antille | Siobhan Boyce | Karen Branch | Katherine Broderick | J. Carney | G. Daley | Susan P. Davidson | Ashley Elliman | Liz Fedirko | Pamela J. Forde | S. Grimmel | Kathleen A. Grinke | K. Hall | H. Heller | Deborah Henault | Chantal Kayitesi | V. LaValle | Sarah Luthern | Natasha Ly | J. Marchewka | Brittani Martino | Ilan Millstrom | Noah Miranda | Christian Nambu | Marjorie Noone | Christine Ommerborn | Lois Chris Pacheco | Nicole Phan | F. A. Porto | Alexandra Reissis | Francis Ruzicka | E. Ryan | K. Selleck | Sue Slaughenhaupt | Elizabeth Suschana | Alicja Trocha-Piechocka | Vivine Wilson | Edward Demers | Jonathan Z. Li | Ashlin R. Michell | Jonathan K. Fallon | Andrew T. Chan | B. A. Abayneh | Susan P Davidson | Pamela J Forde | N. Ly | Xu G. Yu | Xu G. Yu
[1] A. Wald,et al. Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals , 2021, PLoS pathogens.
[2] D. Jarrossay,et al. Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2 , 2021, Science.
[3] A. Sette,et al. Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers , 2021, The Journal of infectious diseases.
[4] W. Greene,et al. Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19 , 2021, Cell Reports.
[5] Gavin J. D. Smith,et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients , 2021, Cell Reports.
[6] F. Ay,et al. Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8+ T cells , 2021, Science Immunology.
[7] Bjoern Peters,et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.
[8] C. Dutertre,et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection , 2020, bioRxiv.
[9] P. Rosenstiel,et al. Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19 , 2020, Immunity.
[10] J. Jardine,et al. SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals. , 2020, Journal of immunology.
[11] M. Malim,et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans , 2020, Nature Microbiology.
[12] R. V. van Lier,et al. Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients , 2020, European journal of immunology.
[13] H. Rammensee,et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition , 2020, Nature immunology.
[14] M. Fehlings,et al. Ontogeny of different subsets of yellow fever virus-specific circulatory CXCR5+ CD4+ T cells after yellow fever vaccination , 2020, Scientific Reports.
[15] Steven M. Holland,et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.
[16] Jacques Fellay,et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.
[17] J. Greenbaum,et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.
[18] Henry A. Utset,et al. SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike , 2020, bioRxiv.
[19] P. Sopp,et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 , 2020, Nature Immunology.
[20] Kelsey K. Finn,et al. Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19 , 2020, Cell.
[21] L. Carter,et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19 , 2020, medRxiv.
[22] S. Mallal,et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.
[23] U. Reimer,et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.
[24] Eric Song,et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.
[25] Sasikanth Manne,et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications , 2020, Science.
[26] Martin Linster,et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.
[27] Morten Nielsen,et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.
[28] X. Tang,et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.
[29] D. Lauffenburger,et al. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production , 2020, Cell.
[30] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[31] Li Yang,et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis , 2020, International Journal of Infectious Diseases.
[32] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[33] Jennifer G. Abelin,et al. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction. , 2019, Immunity.
[34] Alessandro Sette,et al. The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..
[35] M. Pepper,et al. Generation of Allergen-Specific Tetramers for a Murine Model of Airway Inflammation. , 2018, Methods in molecular biology.
[36] Peipei Xu,et al. A systemic review and meta-analysis , 2017 .
[37] R. Baric,et al. Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses , 2016, Immunity.
[38] Alessandro Sette,et al. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. , 2013, Immunity.
[39] A. Luster,et al. Lung dendritic cells imprint T cell lung homing and promote lung immunity through the chemokine receptor CCR4 , 2013, The Journal of experimental medicine.
[40] P. Dash,et al. Quantitative impact of thymic selection on Foxp3+ and Foxp3− subsets of self-peptide/MHC class II-specific CD4+ T cells , 2011, Proceedings of the National Academy of Sciences.
[41] Marion Pepper,et al. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. , 2007, Immunity.